Whoever said there's no such thing as bad publicity never worked in pharma. The latest proof of bad news-related suffering: A new report on antipsychotic drugs finds Janssen's Risperdal and AstraZeneca's Seroquel overtaking Eli Lilly's Zyprexa.
Some 86 percent of doctors have cut their use of Zyprexa because of problems with weight gain and diabetes, the study found. These are the very side effects that captured so much attention late last year, when clinical trial data about them was leaked to The New York Times.
- read this release [1]ļ¾ from research firm Decision Resources
Related Articles:
Lilly ignored Zyprexa safety data on weight, blood sugar. Report [2]
Lilly to pay $500M to settle Zyprexa claims. Report [3]
NIH doctors slam Lilly's marketing tactics. Report [4]